Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
Alamar Biosciences expanded its strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures to include profiling of 86,000 additional plasma samples using the NULISAseq Neuro 220 panel. The expanded project targets a completion date of 2027 and is expected to produce the largest study of neurodegenerative disease with more than 140,000 total samples across diverse cohorts.
Key figures
- Biomarker targets
- 220
- Additional samples
- 86000
- Total projected samples
- 140000
- National initiative samples
- 21000
- Previously profiled samples
- 55000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.